NCT03082534 · OUTCOME

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma · Source last updated 2026-10-01

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months

What was measured

Description, grade (per CTCAE v4.03), seriousness and relatedness

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Description, grade (per CTCAE v4.03), seriousness and relatedness
reporting Status: NOT_POSTED
time Frame: Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months
title: Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice